Long-term follow-up presented at the 2025 ASH Annual Meeting showed gilteritinib in combination with venetoclax and azacitidine delivered a median overall survival of 29.7 months in newly diagnosed FLT3-mutated acute myeloid leukemia. The update reinforces the durability signal for a triplet approach in a high-risk genomic subset. The report focuses on extended outcomes rather than short-term response measures, giving trial stakeholders more data to compare against other front-line FLT3 strategies. The results are tied to the specific regimen of gilteritinib plus venetoclax and azacitidine rather than gilteritinib monotherapy. For clinicians and payers, the key actionability is the magnitude and persistence of survival outcomes in a space where OS duration is often the deciding metric for treatment adoption.
Get the Daily Brief